|
Pyrazinamide (Pyrazinamide)
|
|
Systemic anti-infective
|
|
Antituberculosal agent
|
|
Active Tuberculosis in adults and children, in combination with other drugs.
|
|
15 to 30 mg/kg once daily, before or after meals.
|
|
Category C
|
|
Fever, nausea, vomiting, mild rash, decreased appetite, thrombocytopenia, malaise, dysuria, temporarily decreased 17-ketosteroid levels, arthralgia, urticaria.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|